321 results on '"Netterlid E"'
Search Results
2. Aluminum-Allergen of the Year 2022.
- Author
-
Bruze M, Netterlid E, and Siemund I
- Subjects
- Adult, Child, Dermatitis, Allergic Contact etiology, Humans, Allergens adverse effects, Aluminum adverse effects, Aluminum Compounds adverse effects, Dermatitis, Allergic Contact diagnosis, Patch Tests methods
- Abstract
Abstract: Exposure to elemental aluminum and its salts is unavoidable. Aluminum as a metal is present in transport, construction, packaging, and electronic equipment. Aluminum salts are present in consumer products, food items and drinking water, vaccines, drugs, and antiperspirants. Aluminum in vaccines and preparations for allergen-specific immunotherapy are the major sensitization sources. The predominent clinical manifestations of aluminum allergy are pruritic subcutaneous nodules and eczematous dermatitis. Patch testing shall be performed with aluminum chloride hexahydrate (ACH) in petrolatum. The preparation with ACH 10% detects substantially more aluminum allergy than ACH 2%. A patch test with elemental aluminum, for example, an empty Finn Chamber, is only positive when there is a strong aluminum allergy. A patch test reading should be performed 1 week after the application so as not to miss 15% to 20% of aluminum allergy. Aluminum should be included in any baseline patch test series for children and investigated for a possible inclusion in baseline series for adults. Aluminum test chambers can interfere with the testing resulting in both false-negative and false-positive patch test reactions to nonaluminum contact sensitizers., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Patch testing with aluminum chloride hexahydrate in petrolatum.
- Author
-
Bruze M, Mowitz M, Netterlid E, Siemund I, and Svedman C
- Subjects
- Allergens, Child, Child, Preschool, Humans, Infant, Petrolatum, Aluminum Chloride, Patch Tests methods
- Published
- 2020
- Full Text
- View/download PDF
4. Is there an induction of aluminium contact allergy in children/ adults receiving hyposensitization therapy?: FC4.04
- Author
-
Netterlid, E., Hindsén, M., Siemund, I., Björk, J., Güner, N., and Bruze, M.
- Published
- 2010
5. Young atopics may have clinically relevant contact allergies: FS04.2
- Author
-
Netterlid, E., Hindsén, M., Ekqvist, S., and Bruze, M.
- Published
- 2008
6. Contact allergy to aluminium after hyposensitization therapy
- Author
-
Netterlid, E., Hindsén, M., Henricson, K. Å., Güner, N., Björk, J., and Bruze, M.
- Published
- 2006
7. Persistent itching nodules after the fourth dose of diphtheria–tetanus toxoid vaccines without evidence of delayed hypersensitivity to aluminium
- Author
-
Netterlid, E, Bruze, M, Hindsén, M, Isaksson, M, and Olin, P
- Published
- 2004
- Full Text
- View/download PDF
8. Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years
- Author
-
Carlsson, R. M., Gustafsson, L., Hallander, H. O., Ljungman, M., Olin, P., Gothefors, L., Nilsson, Lennart, Netterlid, E., Carlsson, R. M., Gustafsson, L., Hallander, H. O., Ljungman, M., Olin, P., Gothefors, L., Nilsson, Lennart, and Netterlid, E.
- Abstract
Prior study children from a DTaP efficacy trial were recruited at ages 5 and 15 years to randomized booster trials addressing immunogenicity and reactogenicity; 475 preschool children received mixed or separate injections of a reduced antigen vaccine (Tdap5, Sanofi Pasteur MSD) and an inactivated polio vaccine, and 230 adolescents received the same or another booster vaccine (Tdap1, SSI, Denmark). Pre-vaccination antibody concentrations against pertussis antigens were significantly higher at 15 than 5 years of age, probably due to natural boosting between the studies. Tdap5 induced comparable anti-PT concentrations at both ages, but antibody responses were significantly higher to filamentous haemagglutinin, pertactin and fimbriae 2/3 in adolescents. As expected, a higher amount of PT (Tdap1, 20 mu g) induced a stronger anti-PT response than a lower amount (Tdap5, 2.5 mu g). The frequency of adverse events was low and there were no serious adverse reactions. All local reactions had an early onset and a short duration. A large swelling or redness of more than half of the upper arm circumference was reported in 8/475 5-year-olds and in 6/230 15-year-olds. Children vaccinated with Tdap5 reported more moderate pain in adolescence than at preschool age, whereas itching was only reported in preschool children. Sweden introduced DTaP vaccines in 1996 after a 17-year hiatus with no general pertussis vaccination and pertussis was still endemic at the time of the studies. The frequency of adverse events was nevertheless low in both preschool children and adolescents and antibody responses were adequate. These studies document immunogenicity and reactogenicity in a trial cohort consecutively vaccinated with acellular pertussis vaccines from infancy to adolescence. (C) 2015 Elsevier Ltd. All rights reserved., Funding Agencies|Aventis Pasteur Limited, Toronto, Canada; Aventis Pasteur MSD A/S, Copenhagen, Denmark; Sanofi Pasteur MSD Sweden; Statens Serum Institut (SSI) Denmark
- Published
- 2015
- Full Text
- View/download PDF
9. Vaccination and allergy: EAACI position paper, practical aspects.
- Author
-
Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC, Gomes E, Jenmalm MC, Lau S, Netterlid E, Schwarze J, Sheikh A, Storsaeter J, Skevaki C, Terreehorst I, and Zanoni G
- Subjects
- Child, Child, Preschool, Humans, Hypersensitivity immunology, Infant, Vaccines immunology, Anaphylaxis immunology, Hypersensitivity etiology, Vaccination adverse effects, Vaccines adverse effects
- Abstract
Immunization is highly effective in preventing infectious diseases and therefore an indispensable public health measure. Allergic patients deserve access to the same publicly recommended immunizations as non-allergic patients unless risks associated with vaccination outweigh the gains. Whereas the number of reported possible allergic reactions to vaccines is high, confirmed vaccine-triggered allergic reactions are rare. Anaphylaxis following vaccination is rare, affecting <1/100 000, but can occur in any patient. Some patient groups, notably those with a previous allergic reaction to a vaccine or its components, are at heightened risk of allergic reaction and require special precautions. Allergic reactions, however, may occur in patients without known risk factors and cannot be predicted by currently available tools. Unwarranted fear and uncertainty can result in incomplete vaccination coverage for children and adults with or without allergy. In addition to concerns about an allergic reaction to the vaccine itself, there is fear that routine childhood immunization may promote the development of allergic sensitization and disease. Thus, although there is no evidence that routine childhood immunization increases the risk of allergy development, such risks need to be discussed., (© 2017 The Authors. Pediatric Allergy and Immunology Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
10. Does Allergen-specific Immunotherapy Induce Contact Allergy to Aluminium?
- Author
-
Netterlid, E, primary, Hindsén, M, additional, Siemund, I, additional, Björk, J, additional, Werner, S, additional, Jacobsson, H, additional, Güner, N, additional, and Bruze, M, additional
- Published
- 2013
- Full Text
- View/download PDF
11. Contact allergy in atopic individuals in relation to allergen-specific immunotherapy.
- Author
-
Siemund I, Hindsén M, Netterlid E, Güner N, and Bruze M
- Subjects
- Adolescent, Adult, Dermatitis, Allergic Contact immunology, Dermatitis, Atopic immunology, Female, Humans, Male, Patch Tests, Risk Factors, Single-Blind Method, Young Adult, Allergens immunology, Dermatitis, Allergic Contact complications, Dermatitis, Allergic Contact therapy, Dermatitis, Atopic complications, Desensitization, Immunologic
- Abstract
Type I sensitizations and atopic dermatitis (AD) often appear in the same patient. Beneficial effects of allergen-specific immunotherapy (ASIT) in patients with both AD and type I allergies have been reported. The predisposing role of AD to the development of type IV sensitization is discussed. Whether ASIT for type I allergy also influences type IV allergies is unknown. To compare the number of contact allergies between patients with and without AD, before and after one year's treatment with ASIT. A controlled, single-blind multicentre study of children/adults with allergic asthma and/or rhinoconjunctivitis, treated or untreated with ASIT, was performed. The history of AD was collected using questionnaires. The number of contact allergies was assessed by patch testing with a baseline series. 205 individuals completed the study; 133 treated with ASIT (exposed) and 72 before starting ASIT (unexposed). For participants with AD, significantly more contact allergies were found in the groups of all children (p = 0.002), all exposed children (p<0.001), and all exposed study persons (p = 0.013). Independent of AD, significantly more contact allergies were noted in the groups of all unexposed adults (p = 0.004) and all unexposed study persons (p = 0.004). The higher number of contact allergies in patients with AD indicates that AD may be a risk factor for type IV sensitization in those with allergic asthma and/or rhinoconjunctivitis. The lower number of contact allergies in patients exposed to ASIT suggests an immunomodulatory effect on type IV sensitization.
- Published
- 2016
- Full Text
- View/download PDF
12. Highest Vaccine Uptake after School-Based Delivery - A County-Level Evaluation of the Implementation Strategies for HPV Catch-Up Vaccination in Sweden.
- Author
-
Rehn M, Uhnoo I, Kühlmann-Berenzon S, Wallensten A, Sparén P, and Netterlid E
- Subjects
- Adolescent, Adult, Female, Humans, Sweden, Delivery of Health Care, Papillomavirus Vaccines administration & dosage, Registries, Schools, Vaccination
- Abstract
Background: The Swedish school-based vaccination programme offers HPV vaccine to girls born ≥1999 in 5-6th grade. In 2012, all counties introduced free-of-charge catch-up vaccination campaigns targeting girls born 1993-1998. Varying vaccine uptake in the catch-up group by December 2012 suggested that some implementation strategies were more successful than others. In order to inform future vaccination campaigns, we assessed the impact of different implementation strategies on the county-level catch-up vaccine uptake., Methods: We conducted an ecological study including all Swedish counties (n = 21), asking regional health offices about the information channels they used and where vaccination of the catch-up target group took place in their counties. The uptake of ≥1 dose by 30 September 2014 was estimated using data from the voluntary national vaccination register. We investigated associations between counties' catch-up vaccine uptake, information channels and vaccination settings by calculating incidence rate ratios (IRR) and 95% confidence intervals (CI), using negative binomial regression models., Results: County level catch-up vaccine uptake varied between 49-84%. All counties offered vaccination through primary health care settings. Apart from this eight (34%) also offered the vaccine in some of their schools, four (19%) in all their schools, and two (10%) in other health care centres. The information channels most frequently used were: information at the national on-line health care consulting web-page (100%), letter/invitations (90%), and advertisement (81%). Counties offering vaccination to girls in all schools and counties offering vaccination in some of their schools, reached higher vaccine uptake compared to counties not offering vaccination in any of their schools (all schools adjusted IRR: 1.3, 95% CI: 1.1-1.5, some schools adjusted IRR: 1.2, 95% CI: 1.1-1.3)., Conclusion: Counties offering HPV vaccination to catch-up groups in schools reached the highest vaccine uptake. No information channel explained differences in county-level vaccine uptake. Our findings suggest that catch-up vaccination outside the national vaccination program can reach a high uptake at the population level if it is implemented primarily with an organized delivery (e.g. in schools).
- Published
- 2016
- Full Text
- View/download PDF
13. The Participation of HPV-Vaccinated Women in a National Cervical Screening Program: Population-Based Cohort Study.
- Author
-
Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlström L, Uhnoo I, Netterlid E, Dillner J, Sparén P, and Sundström K
- Subjects
- Adult, Cohort Studies, Female, Follow-Up Studies, Humans, Incidence, Male, Papillomaviridae physiology, Papillomavirus Infections virology, Prognosis, Sweden epidemiology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms epidemiology, Vaccination statistics & numerical data, Young Adult, Mass Screening psychology, Papillomavirus Infections diagnosis, Papillomavirus Infections psychology, Papillomavirus Vaccines therapeutic use, Patient Participation, Uterine Cervical Neoplasms virology, Vaccination psychology
- Abstract
Background: Concerns have been raised that HPV-vaccination might affect women's cervical screening behavior. We therefore investigated the association between opportunistic HPV-vaccination and attendance after invitation to cervical screening., Methods: A cohort of all women resident in Sweden, born 1977-1987 (N=629,703), and invited to cervical screening, was followed October 2006 - December 2012. Invitations to screening were identified via the National Quality Register for Cervical Cancer Prevention, as was the primary outcome of a registered smear. Vaccination status was obtained from two nationwide health data registers. Hazard ratios (HR) were estimated using Cox regression adjusted for age, education level and income (HRadj). Women were individually followed for up to 6 years, of which the first and second screening rounds were analyzed separately., Results: Screening attendance after three years of follow-up was 86% in vaccinated women (N=4,897) and 75% in unvaccinated women (N=625,804). The crude HR of screening attendance in vaccinated vs. unvaccinated women was 1.31 (95% CI 1.27-1.35) in the first screening round. Adjustment for education and income reduced but did not erase this difference (HRadj=1.09, 95% CI 1.05-1.13). In the second screening round, attendance was likewise higher in HPV-vaccinated women (crude HR=1.26, 95% CI 1.21-1.32; HRadj=1.15, 95% CI 1.10-1.20)., Conclusions: HPV-vaccination is so far associated with equal or higher attendance to cervical screening in Sweden in a cohort of opportunistically vaccinated young women. Most but not all of the difference in attendance was explained by socioeconomic differences between vaccinated and unvaccinated women. HPV vaccine effectiveness studies should consider screening attendance of HPV-vaccinated women when assessing incidence of screen-detected cervical lesions.
- Published
- 2015
- Full Text
- View/download PDF
14. Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.
- Author
-
Luxi, Nicoletta, Ciccimarra, Francesco, Bellitto, Chiara, Raethke, Monika, van Hunsel, Florence, Lieber, Thomas, Mulder, Erik, L'Abbate, Luca, Marques, Francisco Batel, Furci, Fabiana, Farcas, Andreea, Giele-Eshuis, Janneke, Morton, Kathryn, Sonderlichová, Simona, Thurin, Nicolas H., Villalobos, Felipe, Riefolo, Fabio, Sturkenboom, Miriam C., and Trifirò, Gianluca
- Subjects
VACCINATION complications ,BOOSTER vaccines ,COVID-19 vaccines ,VACCINE safety ,WATCHFUL waiting - Abstract
Background: Conventional vaccines rarely cause severe allergic reactions. However, the rapid development and approval of COVID-19 vaccines left limited initial data on their adverse reactions, particularly in individuals with a history of allergy. The aim of this study was to assess and compare the safety profile of different doses and brands of COVID-19 vaccines in subjects with a history of allergy vs. those without a history of allergy. Methods: From February 2021 to February 2023, a web-based prospective study gathered vaccinee-reported outcomes using electronic questionnaires across eleven European countries. Baseline and up to six follow-up questionnaires captured data on vaccinee demographics, as well as both solicited and unsolicited adverse reactions. Results: Overall, 3476 vaccinees with a history of allergy were matched with 13,872 vaccinees from the general population at the first vaccination cycle and were included in the analysis. A total of 825 vaccinees with a history of allergy who had received a booster dose, matched to 3297 vaccinees from the general population, were included in the analysis. Higher rates of ADRs occurred after the first vaccination cycle compared to after the booster dose (64–91% vs. 56–79%). However, most reported ADRs were solicited and not serious, and no case of anaphylaxis was reported. Women and vaccinees with a history of allergy reported ADRs more frequently than men and the matched controls, respectively. Compared to other COVID-19 vaccines, a higher proportion of vaccinees experiencing at least one ADR following their first vaccination cycle was observed with Comirnaty and Vaxzevria. Statistically significant differences were observed among the study cohorts for median TTO after the second dose, and for median TTR following the first vaccination cycle and booster dose (p < 0.001). Conclusions: Typically, any drug or vaccine use carries a risk of severe allergic reactions, yet the benefits of vaccination generally outweigh these potential risks, as shown with the COVID-19 vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination.
- Author
-
Bao, Wanying, He, Xinlin, Huang, Yue, Liu, Rongyu, and Li, Zhengyu
- Subjects
HUMAN papillomavirus vaccines ,HUMAN papillomavirus ,GENITAL warts ,VACCINATION coverage ,BUDGET - Abstract
The human papillomavirus (HPV) vaccine was initially approved for a three-dose regimen. Due to resource limitations, budget constraints, low acceptance, and poor adherence, global vaccination coverage is only 15%. A single-dose regimen could simplify logistics, reduce costs, and improve accessibility. However, its clinical effectiveness remains debatable. This review systematically searched PubMed, Embase, and Cochrane Library, including 42 clinical studies, to assess the effectiveness of a single-dose HPV vaccination for preventing HPV infections, cervical abnormalities, and genital warts. We summarized the effectiveness of bivalent, quadrivalent, and nonavalent vaccines across different age groups and buffer periods, and analyzed the factors contributing to the inconsistency of results. The review also provides insights into designing robust future research to inform single-dose HPV vaccination policies and guidelines, highlighting the need for further research to refine vaccination strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. "I Thought It Was Better to Be Safe Than Sorry": Factors Influencing Parental Decisions on HPV and Other Adolescent Vaccinations for Students with Intellectual Disability and/or Autism in New South Wales, Australia.
- Author
-
Carter, Allison, Klinner, Christiane, Young, Alexandra, Strnadová, Iva, Wong, Horas, Vujovich-Dunn, Cassandra, Newman, Christy E., Davies, Cristyn, Skinner, S. Rachel, Danchin, Margie, Hynes, Sarah, and Guy, Rebecca
- Subjects
HEALTH attitudes ,YOUNG adults ,HUMAN papillomavirus ,VACCINE hesitancy ,PARENT attitudes - Abstract
The uptake of human papilloma virus (HPV) and other adolescent vaccinations in special schools for young people with disability is significantly lower than in mainstream settings. This study explored the factors believed to influence parental decision making regarding vaccine uptake for students with intellectual disability and/or on the autism spectrum attending special schools in New South Wales, Australia, from the perspective of all stakeholders involved in the program. Focus groups and interviews were conducted with 40 participants, including parents, school staff, and immunisation providers. The thematic analysis identified two themes: (1) appreciating diverse parental attitudes towards vaccination and (2) educating parents and managing vaccination questions and concerns. While most parents were described as pro-vaccination, others were anti-vaccination or vaccination-hesitant, articulating a marked protectiveness regarding their child's health. Reasons for vaccine hesitancy included beliefs that vaccines cause autism, concerns that the vaccination may be traumatic for the child, vaccination fatigue following COVID-19, and assumptions that children with disability will not be sexually active. Special school staff regarded the vaccination information pack as inadequate for families, and nurses described limited educational impact resulting from minimal direct communication with parents. More effective communication strategies are needed to address vaccine hesitancy among parents with children with disability. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Pertussis-specific memory B-cell and humoral IgG responses in adolescents after a fifth consecutive dose of acellular pertussis vaccine.
- Author
-
Jahnmatz M, Ljungman M, Netterlid E, Jenmalm MC, Nilsson L, and Thorstensson R
- Subjects
- Adhesins, Bacterial immunology, Adolescent, Bacterial Outer Membrane Proteins immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Female, Humans, Male, Sweden, Treatment Outcome, Virulence Factors, Bordetella immunology, Whooping Cough immunology, Antibodies, Viral blood, B-Lymphocyte Subsets immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Immunization, Secondary methods, Immunoglobulin G blood, Immunologic Memory, Whooping Cough prevention & control
- Abstract
In order to impede the increase in pertussis incidence in the adolescent group, a school-leaving booster dose administered at the age of 14 to 16 years will be introduced in Sweden in 2016. Preceding this introduction, an open-label, randomized, multicenter, clinical trial without a control group and with blinded analysis was performed, investigating both safety and immunogenicity. Reported here are the memory B-cell and serological responses detected in a smaller cohort (n = 34) of the 230 subjects recruited to the study. All subjects had received primary vaccination consisting of three doses of diphtheria-tetanus-5-component pertussis (DTaP5) vaccine, at 3, 5, and 12 months of age, and a tetanus-low-dose diphtheria-5-component pertussis (Tdap5) vaccine booster at 5.5 years. In this study, the subjects were randomly assigned and received either a Tdap1 or Tdap5 booster. Of the 230 participants, 34 subjects had samples available for evaluation of IgG-producing memory B-cell responses. Both vaccine groups had significant increases in pertussis toxin-specific serum IgG levels, but only the 1-component group showed significant increases in pertussis toxin-specific memory B cells. The 5-component group had significant increases in filamentous hemagglutinin- and pertactin-specific memory B-cell and serum IgG levels; these were not seen in the 1-component group, as expected. In conclusion, this study shows that a 5th consecutive dose of an acellular pertussis vaccine induces B-cell responses in vaccinated adolescents. (This study has been registered at EudraCT under registration no. 2008-008195-13 and at ClinicalTrials.gov under registration no. NCT00870350.)., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
18. Young individuals with atopic disease and asthma or rhinoconjunctivitis may have clinically relevant contact allergies.
- Author
-
Netterlid E, Hindsén M, Ekqvist S, Henricson KA, and Bruze M
- Subjects
- Adolescent, Allergens administration & dosage, Asthma epidemiology, Child, Comorbidity, Dermatitis, Atopic diagnosis, Dermatitis, Atopic epidemiology, Female, Germany epidemiology, Humans, Male, Patch Tests statistics & numerical data, Rhinitis, Allergic, Perennial diagnosis, Rhinitis, Allergic, Perennial epidemiology, Rhinitis, Allergic, Seasonal diagnosis, Rhinitis, Allergic, Seasonal epidemiology, Risk Assessment, Dermatitis, Allergic Contact diagnosis, Dermatitis, Allergic Contact epidemiology, Hypersensitivity, Immediate diagnosis, Hypersensitivity, Immediate epidemiology, Severity of Illness Index
- Abstract
Background: Children and adolescents with atopic disease who have allergic asthma and/or rhinitis with and without atopic dermatitis may have hidden, clinically relevant contact allergies., Objective: The objective of this study was to survey contact allergies in children and adolescents who had been offered allergen-specific immunotherapy and accepted (exposed)/not accepted (unexposed) such treatment., Methods: Thirty-seven exposed and 24 unexposed individuals with atopic disease were patch tested with a standard series supplemented with aluminum chloride hexahydrate, an empty Finn Chamber, and 8 antigen preparations., Results: In the exposed group, 18 allergies were detected in 13 individuals with atopic disease when excluding reactions to aluminum and antigen preparations, whereas the corresponding figures for the unexposed group were 9 and 6, respectively (non-significant difference). Independent of the allergen-specific immunotherapy, significantly more (P = 0.013) individuals with atopic dermatitis had at least 1 contact allergy. Clinically relevant allergies were represented by sesquiterpene lactone mix, para-tertiary butylphenol-formaldehyde resin, tixocortol pivalate, and colophony., Conclusions: Clinically relevant contact allergies are not uncommon in children and adolescents with atopic disease, which is why patch testing always should be considered in the management of dermatitis in individuals with atopic disease.
- Published
- 2014
- Full Text
- View/download PDF
19. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
- Author
-
Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, Netterlid E, Sparén P, and Arnheim-Dahlström L
- Subjects
- Adolescent, Child, Cohort Studies, Cost-Benefit Analysis, Female, Human papillomavirus 11, Human papillomavirus 6, Humans, Incidence, Registries statistics & numerical data, Sweden epidemiology, Uterine Cervical Neoplasms prevention & control, Young Adult, Condylomata Acuminata epidemiology, Condylomata Acuminata prevention & control, Papillomavirus Infections prevention & control, Papillomavirus Vaccines administration & dosage, Vaccination statistics & numerical data
- Abstract
Importance: Determining vaccine dose-level protection is essential to minimize program costs and increase mass vaccination program feasibility. Currently, a 3-dose vaccination schedule is recommended for both the quadrivalent and bivalent human papillomavirus (HPV) vaccines. Although the primary goal of HPV vaccination programs is to prevent cervical cancer, condyloma related to HPV types 6 and 11 is also prevented with the quadrivalent vaccine and represents the earliest measurable preventable disease outcome for the HPV vaccine., Objective: To examine the association between quadrivalent HPV vaccination and first occurrence of condyloma in relation to vaccine dose in a population-based setting., Design, Setting, and Participants: An open cohort of all females aged 10 to 24 years living in Sweden (n = 1,045,165) was followed up between 2006 and 2010 for HPV vaccination and first occurrence of condyloma using the Swedish nationwide population-based health data registers., Main Outcomes and Measures: Incidence rate ratios (IRRs) and incidence rate differences (IRDs) of condyloma were estimated using Poisson regression with vaccine dose as a time-dependent exposure, adjusting for attained age and parental education, and stratified on age at first vaccination. To account for prevalent infections, models included a buffer period of delayed case counting., Results: A total of 20,383 incident cases of condyloma were identified during follow-up, including 322 cases after receipt of at least 1 dose of the vaccine. For individuals aged 10 to 16 years at first vaccination, receipt of 3 doses was associated with an IRR of 0.18 (95% CI, 0.15-0.22) for condyloma, whereas receipt of 2 doses was associated with an IRR of 0.29 (95% CI, 0.21-0.40). One dose was associated with an IRR of 0.31 (95% CI, 0.20-0.49), which corresponds to an IRD of 384 cases (95% CI, 305-464) per 100,000 person-years, compared with no vaccination. The corresponding IRDs for 2 doses were 400 cases (95% CI, 346-454) and for 3 doses, 459 cases (95% CI, 437-482). The number of prevented cases between 3 and 2 doses was 59 (95% CI, 2-117) per 100,000 person-years., Conclusions and Relevance: Although maximum reduction in condyloma risk was seen after receipt of 3 doses of quadrivalent HPV vaccine, receipt of 2 vaccine doses was also associated with a considerable reduction in condyloma risk. The implications of these findings for the relationship between number of vaccine doses and cervical cancer risk require further investigation.
- Published
- 2014
- Full Text
- View/download PDF
20. Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell responses.
- Author
-
Jahnmatz M, Kesa G, Netterlid E, Buisman AM, Thorstensson R, and Ahlborg N
- Subjects
- Adolescent, Adult, Antibodies, Anti-Idiotypic immunology, Antibodies, Monoclonal immunology, Biotinylation, Cells, Cultured, CpG Islands immunology, Humans, Imidazoles immunology, Interleukin-10 immunology, Interleukin-2 immunology, Lymphocyte Activation, Sensitivity and Specificity, Time Factors, Toll-Like Receptors agonists, Toll-Like Receptors metabolism, B-Lymphocytes immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Enzyme-Linked Immunospot Assay, Immunoglobulin G metabolism, Immunologic Memory
- Abstract
B-cell responses after infection or vaccination are often measured as serum titers of antigen-specific antibodies. Since this does not address the aspect of memory B-cell activity, it may not give a complete picture of the B-cell response. Analysis of memory B cells by ELISpot is therefore an important complement to conventional serology. B-cell ELISpot was developed more than 25 years ago and many assay protocols/reagents would benefit from optimization. We therefore aimed at developing an optimized B-cell ELISpot for the analysis of vaccine-induced human IgG-secreting memory B cells. A protocol was developed based on new monoclonal antibodies to human IgG and biotin-avidin amplification to increase the sensitivity. After comparison of various compounds commonly used to in vitro-activate memory B cells for ELISpot analysis, the TLR agonist R848 plus interleukin (IL)-2 was selected as the most efficient activator combination. The new protocol was subsequently compared to an established protocol, previously used in vaccine studies, based on polyclonal antibodies without biotin avidin amplification and activation of memory B-cells using a mix of antigen, CpG, IL-2 and IL-10. The new protocol displayed significantly better detection sensitivity, shortened the incubation time needed for the activation of memory B cells and reduced the amount of antigen required for the assay. The functionality of the new protocol was confirmed by analyzing specific memory B cells to five different antigens, induced in a limited number of subjects vaccinated against tetanus, diphtheria and pertussis. The limited number of subjects did not allow for a direct comparison with other vaccine studies. Optimization of the B-cell ELISpot will facilitate an improved analysis of IgG-secreting B cells in vaccine studies., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
21. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
- Author
-
Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, Young C, Netterlid E, Sparén P, and Arnheim-Dahlström L
- Subjects
- Adolescent, Adult, Age Factors, Child, Cohort Studies, Condylomata Acuminata virology, Confounding Factors, Epidemiologic, Female, Humans, Incidence, Odds Ratio, Papillomavirus Infections virology, Registries, Socioeconomic Factors, Sweden epidemiology, Treatment Outcome, Alphapapillomavirus immunology, Condylomata Acuminata epidemiology, Condylomata Acuminata prevention & control, Papillomavirus Infections epidemiology, Papillomavirus Infections prevention & control, Papillomavirus Vaccines administration & dosage
- Abstract
Background: Incidence of condyloma, or genital warts (GW), is the earliest possible disease outcome to measure when assessing the effectiveness of human papillomavirus (HPV) vaccination strategies. Efficacy trials that follow prespecified inclusion and exclusion criteria may not be fully generalizable to real-life HPV vaccination programs, which target a broader segment of the population. We assessed GW incidence after on-demand vaccination with quadrivalent HPV vaccine using individual-level data from the entire Swedish population., Methods: An open cohort of girls and women aged 10 to 44 years living in Sweden between 2006 and 2010 (N > 2.2 million) was linked to multiple population registers to identify incident GW in relation to HPV vaccination. For vaccine effectiveness, incidence rate ratios of GW were estimated using time-to-event analyses with adjustment for attained age and parental education level, stratifying on age at first vaccination., Results: A total of 124 000 girls and women were vaccinated between 2006 and 2010. Girls and women with at least one university-educated parent were 15 times more likely to be vaccinated before age 20 years than girls and women whose parents did not complete high school (relative risk ratio = 15.45, 95% confidence interval [CI] = 14.65 to 16.30). Among those aged older than 20 years, GW rates declined among the unvaccinated, suggesting that HPV vaccines were preferentially used by women at high risk of GW. Vaccination effectiveness was 76% (95% CI = 73% to 79%) among those who received three doses of the vaccine with their first dose before age 20 years. Vaccine effectiveness was highest in girls vaccinated before age 14 years (effectiveness = 93%, 95% CI = 73% to 98%)., Conclusions: Young age at first vaccination is imperative for maximizing quadrivalent HPV vaccine effectiveness.
- Published
- 2013
- Full Text
- View/download PDF
22. Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data.
- Author
-
Gidudu JF, Walco GA, Taddio A, Zempsky WT, Halperin SA, Calugar A, Gibbs NA, Hennig R, Jovancevic M, Netterlid E, O'Connor T, Oleske JM, Varricchio F, Tsai TF, Seifert H, and Schuind AE
- Subjects
- Humans, Pain Measurement methods, Terminology as Topic, Immunization adverse effects, Pain diagnosis
- Published
- 2012
- Full Text
- View/download PDF
23. [The Swedish child vaccination program also reaches the children born abroad. Serologic samples show good protection compared to Swedish-born].
- Author
-
Andersson MA, Hallander H, Ljungman M, Norder H, Brytting M, Thorstensson R, and Netterlid E
- Subjects
- Adolescent, Child, Humans, Seroepidemiologic Studies, Sweden epidemiology, Antibodies, Bacterial blood, Antibodies, Viral blood, Emigrants and Immigrants, Mass Vaccination organization & administration, Mass Vaccination standards
- Published
- 2012
24. Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease.
- Author
-
Hallander HO, Lepp T, Ljungman M, Netterlid E, and Andersson M
- Subjects
- Adolescent, Adult, Aged, Antibodies, Bacterial blood, Bacterial Capsules administration & dosage, Child, Child, Preschool, Cross-Sectional Studies, Haemophilus Infections prevention & control, Haemophilus Vaccines administration & dosage, Haemophilus Vaccines standards, Humans, Immunization, Secondary methods, Middle Aged, Seroepidemiologic Studies, Sweden epidemiology, Vaccines, Conjugate administration & dosage, Young Adult, Bacterial Capsules immunology, Haemophilus Infections epidemiology, Haemophilus Infections immunology, Haemophilus Vaccines immunology, Haemophilus influenzae immunology, Immunization methods, Vaccines, Conjugate immunology
- Abstract
The prevalence of IgG ELISA antibodies against Haemophilus influenzae polyribosyl ribitol phosphate (anti-Hib) was studied in two Swedish seroepidemiologic materials. One study was performed in 1997 5 years after the introduction of universal Hib vaccination (N=3320). Ten years later, a similar study was carried out to analyze the effect of vaccination on anti-Hib prevalence (N=2383). The median values of anti-Hib concentrations (EU/mL) were almost identical in the two materials. The antigenic pressure including vaccination, natural infections and possible cross-immunizations was thus assumed to be constant. The joint median was 0.50 EU/mL (95% confidence interval: 0.46, 0.56). However, there were also indications of reduced exposure to 'Hib-antigens' over a 10-year period. The proportion above the cut-off point for protection, 0.15 EU/mL, decreased significantly for children aged 2-19 years from 78% in 1997 to 74% in 2007 (p=0.034), and there was a significant increase in values below the minimal level of detection for adults from 17% in 1997 to 20% in 2007 (p=0.009). In the 2007 material no specific age group could be identified with a lower immune profile than other age groups older than 3 years and there was a significant downward trend of invasive infections caused by Hib according to notification data for the period 1997-2008. Therefore, the conclusion is that presently there is no need for a booster dose of Hib vaccine in Sweden after primary vaccination but the situation should be carefully monitored., (© 2010 The Authors. Journal Compilation © 2010 APMIS.)
- Published
- 2010
- Full Text
- View/download PDF
25. Tracking parental attitudes on vaccination across European countries: The Vaccine Safety, Attitudes, Training and Communication Project (VACSATC).
- Author
-
Stefanoff P, Mamelund SE, Robinson M, Netterlid E, Tuells J, Bergsaker MA, Heijbel H, and Yarwood J
- Subjects
- Adolescent, Adult, Child, Preschool, Cross-Sectional Studies, Europe, Female, Health Care Surveys, Humans, Infant, Interviews as Topic, Male, Surveys and Questionnaires, Young Adult, Health Knowledge, Attitudes, Practice, Parents psychology, Vaccination statistics & numerical data
- Abstract
The paper presents the first results from the European project VACSATC which aimed to track parental attitudes on vaccinations across several European countries. We compared five cross-sectional surveys of parents with children less than 3 years of age in England, Norway, Poland, Spain and Sweden carried out during 2008-2009. Data were collected from 6611 respondents. Two countries used face-to face interviews, one used telephone interviews, and two other countries used mail-in questionnaires. In all countries health professionals were indicated as the most important and trusted source of information on vaccination. The study results also show that parental attitudes on vaccinations in the childhood vaccination programs are generally positive. However, there were differences in attitudes on vaccination between the five countries, possibly reflecting different methods of sampling the respondents, context-specific differences (e.g. level of activity of governmental agencies), but also individual-level parental variation in demographic and socioeconomic status variables., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
26. Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.
- Author
-
Hallander HO, Andersson M, Gustafsson L, Ljungman M, and Netterlid E
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Pertussis Vaccine administration & dosage, Seroepidemiologic Studies, Sweden epidemiology, Vaccination, Whooping Cough immunology, Whooping Cough microbiology, Young Adult, Antibodies, Bacterial blood, Bordetella pertussis immunology, Pertussis Toxin immunology, Pertussis Vaccine immunology, Whooping Cough epidemiology
- Abstract
The prevalence of IgG ELISA antibodies against pertussis toxin (anti-PT) was studied in two Swedish seroepidemiological studies. One was performed in 1997 when the new pertussis vaccination program was 1 year old (n = 3420). In 2007, when Pa vaccines had been used countrywide for 10 years in the universal child vaccination program, this study was repeated to analyze the effect of vaccination on anti-PT prevalence (n = 2379). Before the statistical analysis of seroprevalence, children vaccinated within the last 2 years before the serosurveys were excluded. The results indicate a reduced exposure to Bordetella pertussis in the population. The proportion of sera without measurable anti-PT antibodies increased significantly, aggregated over all comparable age groups, from 3.8% in people sampled in 1997 to 16.3% in people sampled in 2007. For cord blood, 1% was without measurable anti-PT antibodies in 1997 compared to a significantly higher level, 12%, in 2007. With anti-PT concentrations of > or =50 and > or =100 EU/ml as cutoff points for 'recent infection' the proportion above the cutoff points for younger children was significantly higher in 1997 than in 2007 at both cutoff points. For all adults, 20 years of age and older, the difference in proportions above the lower cutoff point was close to statistically significant, comparing 1997 with 2007. This was not the case at 100 EU/ml. In the 1997 samples of children, there was a significant downward trend of 'recent infections' at both cutoff points for three sampled age groups between 5 and 15 years of age from 21% at 5.0-5.5 years of age to 7% at 14.7-15.7 years for the lowest cutoff. In the 2007 samples of children, on the contrary, there was a significant continuous upward trend of 'recent infections', at both cutoff points, for four sampled age groups between 4 and 18 years of age - from 4% at 4-5 years of age to 16% at 17-18 years at the lowest cutoff. The continuous increase, with age of children with high anti-PT concentrations, supports the recent change in the general Swedish childhood vaccination program to include a pre-school booster at 5-6 years and a school-leaving booster at 14-16 years of age.
- Published
- 2009
- Full Text
- View/download PDF
27. Surveillance of vaccine safety: comparison of parental reports with routine surveillance and a clinical trial.
- Author
-
Netterlid E, Månsson ME, and Håkansson A
- Subjects
- Child, Clinical Trials as Topic, Edema etiology, Humans, Injections, Interviews as Topic, Safety, Surveys and Questionnaires, Sweden, Diphtheria-Tetanus Vaccine administration & dosage, Diphtheria-Tetanus Vaccine adverse effects, Immunization, Secondary adverse effects, Sentinel Surveillance
- Abstract
One way to maintain confidence in vaccination programmes is to improve monitoring of immunisation safety. We studied active parental reporting of adverse events after a booster dose of diphtheria-tetanus toxoid (DT). 7193 children received the vaccine. Questionnaires were submitted by 84.2% of the parents, who reported reactions for 9.2% of the children. Four percent of events were classified as moderate/severe by interviews. Relative risk of redness and swelling reported was 0.24 (95% CI, 0.13-0.42) compared to a clinical trial, while it was 71.0 (44-114) compared to passive surveillance. Active surveillance by parental reports is a useful complement to passive surveillance of childhood immunisations to generate hypotheses for evaluation in controlled studies.
- Published
- 2009
- Full Text
- View/download PDF
28. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy.
- Author
-
Netterlid E, Hindsén M, Björk J, Ekqvist S, Güner N, Henricson KA, and Bruze M
- Subjects
- Adolescent, Age Distribution, Chi-Square Distribution, Child, Comorbidity, Cross-Sectional Studies, Dermatitis, Allergic Contact immunology, Desensitization, Immunologic methods, Female, Follow-Up Studies, Humans, Hypersensitivity epidemiology, Hypersensitivity etiology, Hypersensitivity pathology, Incidence, Male, Probability, Pruritus chemically induced, Pruritus pathology, Sensitivity and Specificity, Severity of Illness Index, Sex Distribution, Statistics, Nonparametric, Surveys and Questionnaires, Young Adult, Aluminum adverse effects, Dermatitis, Allergic Contact epidemiology, Dermatitis, Allergic Contact therapy, Desensitization, Immunologic adverse effects, Patch Tests adverse effects, Pruritus epidemiology
- Abstract
Background: The development of persistent itchy nodules at the injection site following hyposensitization therapy with aluminium-precipitated antigen extract has been described in several reports. Occasionally, contact allergy to aluminium has been reported in individuals with such nodules., Objectives: To investigate if hyposensitization therapy can induce contact allergy to aluminium and examine if there is any association between persistent subcutaneous nodules and aluminium allergy., Patients/methods: Sixty-one children with allergic asthma and/or allergic rhinitis participated in the study of whom 37 had had hyposensitization therapy. The study consisted of a non-clinical part based on a questionnaire and a clinical part with a physical examination, self-assessment of itching, and patch testing. To secure an unbiased evaluation of possible reactions, the investigators were blinded., Results: Contact allergy to aluminium was found in eight participants, all in the exposed group (8/37 versus 0/24, P = 0.02). Examination showed nodules on the upper arms in 13 participants, all in the group exposed to hyposensitization therapy. Nodules were over-represented in patients with contact allergy to aluminium., Conclusions: There was a statistically significant association between contact allergy to aluminium and persistent subcutaneous nodules in children who had had hyposensitization therapy.
- Published
- 2009
- Full Text
- View/download PDF
29. A transversal cross-sectional study of factors related to HPV vaccination status and cancer screening participation among French women aged 25–40.
- Author
-
Serman, Fanny, Lisembard, Gabrielle, Sahraoui, Maxence, Berkhout, Christophe, Rochoy, Michaël, Haro, Anthony, and Calafiore, Matthieu
- Subjects
GENITAL warts ,VACCINATION status ,HUMAN papillomavirus vaccines ,EARLY detection of cancer ,CANCER vaccines ,HUMAN papillomavirus ,CANCER education ,ANTI-vaccination movement - Abstract
Background: In 2020, uterine cervical cancer (UCC) was the 12th most common cancer among women in France and the 4th worldwide. French health authorities wanted to increase Human Papilloma Virus (HPV) vaccination and screening rates. There were still many barriers to these measures among young women, their families, and health professionals and teachers. Between 2014 and 2019, international studies found inconsistent effects of HPV vaccination on UCC screening. In 2022, a survey was conducted among women aged 25 to 40 in the Nord-Pas-de-Calais region to assess participation 1) in HPV vaccination and its barriers, 2) in UCC screening as a function of HPV vaccination status. Methods: Data were collected using an anonymous online questionnaire distributed by QR code in 80 general practices randomly selected in the Nord-Pas-de-Calais region between January and June 2022. Results were analyzed bivariately using the Chi2 test, multivariately when numbers allowed, and in age subgroups (sensitivity analysis). Results: 407 complete questionnaires (for 602 participating women) were analyzed. In our sample, 41% of women aged 25 to 40 in the Nord-Pas-de-Calais region were vaccinated against HPV viruses in 2022. The risk factors for non-vaccination, after multivariable adjustment, were: the periods of eligibility for vaccination in the early days of French vaccination (2007–2012: odds ratio OR = 0.04 [95% CI, 0.02–0.09]; 2012–2017: OR = 0.5 [0.3–0.8]), information received from non-medical sources (OR = 0.3 [0.2–0.6]), and absence of information about vaccination (OR = 0.12 [0.05–0.27]). In our sample, 90% of women were screened for UCC. In bivariate analysis, women at risk of not being screened were those who were youngest, had been vaccinated against HPV, were not heterosexual, lived alone, had gynecological follow-up by their general practitioner, and did not have regular gynecological follow-up. Sensitivity analysis showed that the only risk factor significantly correlated with non-screening regardless of age group was lack of regular gynecological follow-up. Conclusions: Participation in HPV vaccination and UCC screening is improved by medical education and gynecological follow-up. This multicenter study, limited by the relative youth of vaccination in France, should be repeated after 2037 to assess the possible effect of vaccination on screening. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Overcoming False-Negative Patch Tests: A Systematic Literature Review.
- Author
-
Massoumi, Shayan, Rizvi, Zehra, Cázares, Ulysses, and Maibach, Howard
- Abstract
Exogenous allergens, found In cosmetic products, jewelry Items, antiseptics and antlbacterlals, plants, and solvents, can cause clinical allergic contact dermatitis (ACD). To help identify and discern which allergen is causing ACD, clinicians use patch tests, but they can yield false-negative results at times. Examining potential reasoning for false negatives is particularly helpful when a patient's history and physical examination strongly suggest ACD, and the patch test is negative. A strong history and physical presentation suggestive of ACD warrants additional patch testing or other methods to verify a false-negative patch test result. We conducted a literature review to compile various reasonings and solutions for false-negative patch tests in suspected ACD patients. Utilizing EMBASE, Scopus, PubMed, and Google Scholars, 49 articles were included by using search terms such as "False negative patch test'' or "False-negative patch test" and "allergic contact dermatitis," or "ACD." Common factors that led to false-negative patch test results include low allergen concentration, inadequate percutaneous penetration, technique error, immunosuppressive therapy, and ultraviolet exposure. Potential solutions include using different vehicles, concentration, increasing reading time, repeating the patch test, intradermal testing, and repeat open application testing. If a false-negative patch test is suspected, then intradermal testing can be administered to ensure the specificity of the patch test result. Considering the main contributing factors and solutions to false-negative patch tests, clinicians can accurately diagnose ACD and administer proper treatment plans. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China.
- Author
-
Wang, Jing, Du, Jian, Liu, Yan, Che, Xinren, Xu, Yuyang, and Han, Jiayin
- Subjects
VACCINATION of children ,PNEUMOCOCCAL vaccines ,VACCINE safety ,FEBRILE seizures ,ALLERGIES ,EPILEPSY - Abstract
With the widespread use of the 13-valent pneumonia vaccine (PCV13) in China, monitoring adverse events following immunization (AEFIs) is critical. We conducted a descriptive analysis of the AEFI occurrences reported within Hangzhou between the years 2020 and 2023, including the temporal trend of case reports and variables such as sex, age, type of PCV13, dose number, type of reporter, cause-specific classification, severity, and onset from vaccination. Vaccine safety signals were analyzed using reporting odds ratios (RORs). Over the 4 years analyzed in the study, 2564 AEFI cases were reported, including seven severe cases. Most AEFIs occurred within 0–1 days after vaccination (2398, 93.53%), with over half affecting infants aged 1.5–6 months of age. No statistically significant difference was observed between PCV13-TT and PCV-CRM197. Seasonal differences in AEFI reports were noted. Positive signals were detected for fever (ROR-1.96SE: 1.64) and persistent crying (ROR-1.96SE: 1.61). Four serious AEFI cases were coincidental events, while three others were considered vaccine-related cases (including one case each of allergic reaction, febrile seizure, and thrombocytopenia). The safety and tolerability of PCV13 are good, and attention should be paid to severe AEFIs, as well as long-term safety disparities between different types of PCV13. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Mechanical Properties of Ti Grade 2 Manufactured Using Laser Beam Powder Bed Fusion (PBF-LB) with Checkerboard Laser Scanning and In Situ Oxygen Strengthening.
- Author
-
Wysocki, Bartlomiej Adam, Chmielewska-Wysocka, Agnieszka, Maj, Piotr, Molak, Rafał Maksymilian, Romelczyk-Baishya, Barbara, Żrodowski, Łukasz, Ziętala, Michał, Nowak, Wojciech, Święszkowski, Wojciech, and Muzyk, Marek
- Subjects
FATIGUE limit ,STRENGTHENING mechanisms in solids ,LASER beams ,SOLUTION strengthening ,MANUFACTURING processes ,LASER fusion ,POWDERS - Abstract
Additive manufacturing (AM) technologies have advanced from rapid prototyping to becoming viable manufacturing solutions, offering users both design flexibility and mechanical properties that meet ISO/ASTM standards. Powder bed fusion using a laser beam (PBF-LB), a popular additive manufacturing process (aka 3D printing), is used for the cost-effective production of high-quality products for the medical, aviation, and automotive industries. Despite the growing variety of metallic powder materials available for the PBF-LB process, there is still a need for new materials and procedures to optimize the processing parameters before implementing them into the production stage. In this study, we explored the use of a checkerboard scanning strategy to create samples of various sizes (ranging from 130 mm
3 to 8000 mm3 using parameters developed for a small 125 mm3 piece). During the PBF-LB process, all samples were fabricated using Ti grade 2 and were in situ alloyed with a precisely controlled amount of oxygen (0.1–0.4% vol.) to enhance their mechanical properties using a solid solution strengthening mechanism. The samples were fabricated in three sets: I. Different sizes and orientations, II. Different scanning strategies, and III. Rods for high-cycle fatigue (HCF). For the tensile tests, micro samples were cut using WEDM, while for the HCF tests, samples were machined to eliminate the influence of surface roughness on their mechanical performance. The amount of oxygen in the fabricated samples was at least 50% higher than in raw Ti grade 2 powder. The O2 -enriched Ti produced in the PBF-LB process exhibited a tensile strength ranging from 399 ± 25 MPa to 752 ± 14 MPa, with outcomes varying based on the size of the object and the laser scanning strategy employed. The fatigue strength of PBF-LB fabricated Ti was 386 MPa, whereas the reference Ti grade 2 rod samples exhibited a fatigue strength of 312 MPa. Our study revealed that PBF-LB parameters optimized for small samples could be adapted to fabricate larger samples using checkerboard ("island") scanning strategies. However, some additional process parameter changes are needed to reduce porosity. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
33. [Risk of confusing the vaccines].
- Author
-
Netterlid E
- Subjects
- Diphtheria-Tetanus-Pertussis Vaccine administration & dosage, Diphtheria-Tetanus-Pertussis Vaccine adverse effects, Drug Combinations, Hepatitis B Vaccines administration & dosage, Hepatitis B Vaccines adverse effects, Humans, Infant, Mumps Vaccine administration & dosage, Mumps Vaccine adverse effects, Risk Factors, Rubella Vaccine administration & dosage, Rubella Vaccine adverse effects, Viral Vaccines administration & dosage, Drug Labeling, Drug Packaging, Viral Vaccines adverse effects
- Published
- 2001
34. VACSATC (vaccine safety: attitudes, training and communication): why such a project?
- Author
-
Alvarez-Pasquín, M. J., Heijbel, H., Yarwood, J., Damme, P., Aksakal, F. N., Andrén, S., Aronsson, B., Augustynowitcz, E., Bechini, A., Bejersten, M., Blennow, M., Bergsaker, M., Boccalini, S., Bonanni, P., Czumbel, I., Fu, C., Gerhardsen, T. I., Grgic-Vitek, M., Habersaat, K., Haugen, I. L., Kerbo, N., Kraigher, A., Lundin, H., Mayer, M. A., Muchl, R., Netterlid, E., Navarro, J. A., Nökleby, H., Pistol, A., Pors Muniz, H., Robinson, M., Stanescu, A., Pawel Stefanoff, Tuells, J., Vladimirova, N., and Vorsters, A.
35. Risk factors for granulomas in children following immunization with aluminium-adsorbed vaccines: A Danish population-based cohort study.
- Author
-
Hoffmann SS, Thiesson EM, Johansen JD, and Hviid A
- Subjects
- Adjuvants, Immunologic adverse effects, Adult, Aluminum adverse effects, Aluminum Compounds, Aluminum Hydroxide, Cohort Studies, Female, Granuloma chemically induced, Granuloma epidemiology, Humans, Male, Phosphates, Risk Factors, Vaccination, Young Adult, Dermatitis, Allergic Contact etiology, Vaccines adverse effects
- Abstract
Background: Aluminium-adsorbed vaccines may in some children cause severely itching nodules at the injection site, known as vaccination granulomas., Objective: To investigate vaccine-, child- and maternal-level risk factors for the development of vaccination granulomas following immunization with aluminium-adsorbed vaccines., Methods: A Danish population-based cohort study with 553 932 children born in Denmark from 1 January 2009 to 31 December 2018, vaccinated with an aluminium-adsorbed vaccine during the first year of life, followed until 31 December 2020. Poisson regression was used to estimate granuloma rate ratios according to the type of adjuvant, accumulated dose of aluminium, timing of vaccination appointments, sex, gestational age, having siblings with granulomas, maternal age and maternal ethnicity., Results: We identified 1901 vaccination granuloma cases (absolute risk, 0.34%). Among vaccine level factors, revaccination (third vs. first vaccination appointment, adjusted rate ratio [RR] 1.26, 95% confidence interval [CI] 1.03-1.55), the specific adjuvant used (aluminium phosphate vs. hydroxide, RR 0.58, 95% CI 0.48-0.70) and dosage (≥1.0 mg vs. <1.0 mg, RR 1.34, 95% CI 1.19-1.52) were associated with risk of granulomas; the timing of vaccination appointments was not. Among child-level factors, female sex (vs. males, RR 1.12, 95% CI, 1.02-1.22), prematurity (vs. term birth, RR 0.71, 95% CI, 0.54-0.93) and having sibling(s) with granulomas (vs. no siblings with granulomas, RR 46.15, 95% CI, 33.67-63.26) were associated with risk of granulomas. Among maternal-level factors, non-Danish ethnicity (vs. Danish, RR 0.51, 95% CI, 0.42-0.63) and young maternal age (<20 years vs. 20-39 years, RR 0.46, 95% CI 0.25-0.83) were associated with risk of granulomas., Conclusions: Several risk factors for vaccination granulomas at the vaccine, child and maternal levels, were identified. Reducing the dose of aluminium or replacing aluminium hydroxide with aluminium phosphate could reduce the risk of granulomas. However, this must be balanced against the potential for reduced immunogenicity., (© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
36. Pretransplant, Th17 dominant alloreactivity in highly sensitized kidney transplant candidates.
- Author
-
Negi, Sarita, Rutman, Alissa K., Chee Loong Saw, Paraskevas, Steven, and Tchervenkov, Jean
- Published
- 2024
- Full Text
- View/download PDF
37. Modularized viromimetic polymer nanoparticle vaccines (VPNVaxs) to elicit durable and effective humoral immune responses.
- Author
-
Huang, Zichao, Zhuang, Xinyu, Liu, Liping, Zhao, Jiayu, Ma, Sheng, Si, Xinghui, Zhu, Zhenyi, Wu, Fan, Jin, Ningyi, Tian, Mingyao, Song, Wantong, and Chen, Xuesi
- Subjects
POLYLACTIC acid ,NANOPARTICLES ,COVID-19 pandemic ,POLYETHYLENE glycol ,SARS-CoV-2 ,ANTIBODY titer ,VIRUS-like particles - Abstract
Virus-like particle (VLP) vaccines had shown great potential during the COVID-19 pandemic, and was thought to be the next generation of antiviral vaccine technology due to viromimetic structures. However, the time-consuming and complicated processes in establishing a current recombinant-protein–based VLP vaccine has limited its quick launch to the out-bursting pandemic. To simplify and optimize VLP vaccine design, we herein report a kind of viromimetic polymer nanoparticle vaccine (VPNVax), with subunit receptor-binding domain (RBD) proteins conjugated to the surface of polyethylene glycol- b -polylactic acid (PEG- b -PLA) nanoparticles for vaccination against SARS-CoV-2. The preparation of VPNVax based on synthetic polymer particle and chemical post-conjugation makes it possible to rapidly replace the antigens and construct matched vaccines at the emergence of different viruses. Using this modular preparation system, we identified that VPNVax with surface protein coverage of 20%–25% had the best immunostimulatory activity, which could keep high levels of specific antibody titers over 5 months and induce virus neutralizing activity when combined with an aluminum adjuvant. Moreover, the polymer nano-vectors could be armed with more immune-adjuvant functions by loading immunostimulant agents or chemical chirality design. This VPNVax platform provides a novel kind of rapidly producing and efficient vaccine against different variants of SARS-CoV-2 as well as other viral pandemics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Human Papillomavirus (HPV) Infection and Risk Behavior in Vaccinated and Non-Vaccinated Paraguayan Young Women.
- Author
-
Bobadilla, María Liz, Villagra, Verónica, Castro, Héctor, von Horoch, Marta, Araya, Soraya, Deluca, Gerardo, and de Paula, Vanessa Salete
- Subjects
PAPILLOMAVIRUSES ,HUMAN papillomavirus ,AT-risk behavior ,VACCINATION ,YOUNG women ,VACCINATION coverage - Abstract
Cervical cancer is a global health concern and ranks fourth among the most prevalent cancers in women worldwide. Human papillomavirus (HPV) infection is a known precursor of cervical cancer and preventive measures include prophylactic vaccines. This study focused on sexually active Paraguayan women aged 18–25 years, exploring the intersection of HPV vaccination and sexual behavior. Among 254 participants, 40.9% received the Gardasil-4 vaccine, with no significant differences in sexual behavior between the vaccinated and unvaccinated sexually active groups. However, a notable decrease in the prevalence of HPV among the vaccinated women highlights the efficacy of this vaccine in reducing infections. The prevalence of any HPV type was 37.5% in vaccinated participants compared to 56.7% in unvaccinated participants (p = 0.0026). High-risk HPV types showed a significant difference, with a prevalence of 26.0% in vaccinated women compared with 52.7% in unvaccinated women (p < 0.001). Although a potential decline in genital warts was observed among the vaccinated individuals, statistical significance (p = 0.0564) was not reached. Despite the challenges in achieving high vaccination coverage, the observed reduction in HPV prevalence underscores the importance of ongoing monitoring, healthcare professional recommendations, and comprehensive risk management. These findings contribute to dispelling concerns about HPV vaccination influencing sexual behavior, advocating further large-scale research to explore the impact of vaccines on various HPV types and potential cross-protection. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women.
- Author
-
Bønløkke, Sara, Blaakær, Jan, Steiniche, Torben, and Iachina, Maria
- Subjects
CERVICAL cancer ,DANES ,SOCIAL factors ,SOCIAL marginality ,OLDER women - Abstract
Background: For cervical cancer (CC), the implementation of preventive strategies has the potential to make cervical cancer occurrence and death largely avoidable. To better understand the factors possibly responsible for cervical cancer, we aimed to examine possible differences in age and social parameters as well as screening status between women with low- or high-stage cervical cancer and matched controls. Methods: Through the Danish Cancer Registry (DCR), women diagnosed with cervical cancer in Denmark between 1987 and 2016 were included. These were age- and residence-matched in a 1:5 ratio with controls from the general female population. The study population was sub grouped into a low-stage subpopulation with women with early-stage cervical cancer and matched controls and a high-stage subpopulation with women with late-stage cervical cancer and matched controls. Age and social parameters were compared within the subpopulations as well as between low- and high-stage cases. For part of the study population, screening attendance was examined to compare differences in adherence. Results: Overall, we found that the risk of cervical cancer is significantly increased in socially disadvantaged women and not least non-attenders in screening. Interestingly, the high-stage subpopulation was significantly older than the low-stage subpopulation (p < 0.001), and when examining the impact of age further, we found that for cervical cancer cases, the risk of having low-stage disease decreases significantly with increasing age, whereas the risk of having high-stage disease increases significantly with increasing age. In the screening cohort, significantly less cases than controls were attenders in screening with the most pronounced differences seen in the old subpopulation (women aged 50–64 years) and in the high-stage subpopulation (p-values all < 0.001). Interestingly, when examining the risk of CC for attenders and non-attenders, we demonstrated that many social parameters continue to influence the risk of cervical cancer, even in women attending screening. Conclusions: Older women, socially disadvantaged women, and non-attenders in screening are particularly vulnerable in terms of developing cervical cancer, especially high-stage disease. Therefore, improvements in the participating rate in screening as well as a revision of the current screening guidelines are needed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. SELF-ASSESSMENT.
- Published
- 2022
- Full Text
- View/download PDF
41. Lack of detection of aluminium‐reactive T‐lymphocytes in patients with SCIT‐induced granulomas.
- Author
-
Hoffmann, Stine Skovbo, Elberling, Jesper, Johansen, Jeanne Duus, and Blom, Lars Heede
- Subjects
T cells ,EOSINOPHILIC granuloma ,GRANULOMA ,MONONUCLEAR leukocytes - Abstract
This article discusses the lack of detection of aluminum-reactive T-lymphocytes in patients with subcutaneous immunotherapy (SCIT)-induced granulomas. Aluminum contact allergy is commonly seen in children with itching vaccination granulomas, but it can also occur in adults following SCIT. The traditional method of detecting sensitization to aluminum is patch testing, but it has limitations. The study investigates the use of the blood in vitro lymphocyte proliferation test (LPT) as an alternative to patch testing. The results suggest that there may be few or no circulating aluminum-reactive cells in adults with SCIT-induced granulomas, and both patch testing and LPT may have low sensitivity for detecting aluminum contact allergy in adults. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
42. Axillary Contact Dermatitis: An Update on Potential Allergens and Management.
- Author
-
Musicante, Meryl J., Cohen, David E., and Milam, Emily C.
- Abstract
The article focuses on the differential diagnosis of dermatoses in the axillae, with an emphasis on contact dermatitis, both irritant and allergic. Topics include common causes of axillary contact dermatitis, clinical presentation, anatomical and environmental factors contributing to sensitivity, and the diagnostic approach involving clinical assessment, patch testing, and histopathology.
- Published
- 2024
- Full Text
- View/download PDF
43. An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster (Tdap Booster)
- Author
-
MCM Vaccines B.V., Statens Serum Institut, and Prof. em. Leif Gothefors
- Published
- 2010
44. Contact Allergy to Two Aluminum Salts in Consecutively Patch-Tested Dermatitis Patients.
- Author
-
Siemund I, Dahlin J, Hindsén M, Zimerson E, Antelmi A, Hamnerius N, Hauksson I, Isaksson M, Pontén A, Mowitz M, Svedman C, and Bruze M
- Subjects
- Adult, Age Factors, Allergens administration & dosage, Aluminum Chloride administration & dosage, Aluminum Compounds adverse effects, Child, Dermatitis, Allergic Contact etiology, Female, Humans, Intradermal Tests methods, Male, Risk Factors, Allergens adverse effects, Aluminum Chloride adverse effects, Dermatitis, Allergic Contact diagnosis, Patch Tests methods
- Abstract
Background: Recently, aluminum chloride hexahydrate (ACH) 10.0% petrolatum (pet) was recommended for patch testing to detect aluminum contact allergy. Aluminum lactate (AL) may be as reliable a test substance as ACH., Objective: We aimed to investigate the frequencies of aluminum allergy when ACH and AL were used in patch testing consecutive patients., Methods: Petrolatum preparations of ACH 10.0% and AL 12.0% were added to the baseline series in 2010-2017. Aluminum chloride hexahydrate 10.0% pet was added to the children baseline series from July 1, 2012, to December 31, 2017., Results: A total of 5448 patients were patch tested with the extended baseline series and 196 children with the extended children baseline series. Forty-eight of the 5448 adults (0.9%) and 10 of the 196 children (5.1%) were diagnosed with aluminum contact allergy. A significant difference was found between the aluminum allergy frequencies in children and adults patch tested with ACH in 2013-2017 (P < 0.001). The difference between the frequencies of contact allergies for the 2 aluminum salts is not statistically significant., Conclusions: Patch testing with ACH and AL demonstrated similar contact allergy frequencies. To detect aluminum allergy, patch testing with ACH 10.0% pet is recommended. Aluminum chloride hexahydrate 10.0% pet should be considered for inclusion in baseline series for patch testing adults and children., Competing Interests: The authors have no funding or conflicts of interest to declare., (Copyright © 2021 American Contact Dermatitis Society. All Rights Reserved.)
- Published
- 2022
- Full Text
- View/download PDF
45. HPV Opportunistic Vaccination: A Literature Review and a Single-Center Experience in Northern Italy through the COVID-19 Pandemic.
- Author
-
Cantatore, Francesco, Agrillo, Nadia, Camussi, Alessandro, and Origoni, Massimo
- Subjects
LITERATURE reviews ,HUMAN papillomavirus vaccines ,GENITAL warts ,COVID-19 pandemic ,VACCINATION coverage ,SECONDARY prevention - Abstract
The World Health Organization (WHO) set the goal of 90% HPV vaccination coverage in the population to eliminate cervical cancer. Opportunistic vaccination is performed outside the free vaccination or catch-up programs. Both free and opportunistic HPV vaccination programs experienced slowdowns during the COVID-19 pandemic. In this retrospective study, we aimed to identify the benefits and the obstacles of opportunistic vaccination among male and female individuals who took advantage of the "on-demand" service offered by San Raffaele Hospital in Milan from April 2018 to May 2023. The impact that the COVID-19 pandemic had on vaccination adherence was also analyzed. Data on a total of 527 subjects were collected from an in-house database and through personal interviews. Women in the cohort of older patients (over 25) adhered to the vaccination schedule more than younger women. Opportunistic vaccination request is influenced by the need of a gynecologist, a general practitioner, or public health clinic availability. Women also showed good adherence to screening, demonstrating awareness of the importance of cervical cancer secondary prevention despite vaccination. Opportunistic vaccination offers the possibility of including individuals excluded from the free vaccination campaigns, often already affected by lesions caused by HPV, providing increased viral clearance and faster lesion regression. The main limit remains the economic burden. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Patch testing with aluminium Finn Chambers could give false-positive reactions in patients with contact allergy to aluminium.
- Author
-
Rosholm Comstedt L, Dahlin J, Bruze M, Hedberg Y, Matura M, and Svedman C
- Subjects
- Adult, False Positive Reactions, Female, Humans, Lidocaine administration & dosage, Male, Myroxylon, Palladium administration & dosage, Perfume administration & dosage, Retrospective Studies, Tetracaine administration & dosage, Allergens administration & dosage, Aluminum adverse effects, Dermatitis, Allergic Contact diagnosis, Patch Tests instrumentation, Patch Tests methods
- Abstract
Background: Earlier laboratory studies have shown that sodium tetrachloropalladate, Myroxylon pereirae, caine mix II, and palladium chloride trigger the release of aluminium (Al) from Finn Chambers (FC)., Objectives: To investigate whether aluminium realease from FC could influence the diagnostic outcome of patch testing with FC., Method: A retrospective analysis of patch test results from 2010 to 2019 was performed. A two-sided Fisher's exact test was used to calculate any overrepresentation of contact allergy to Al among patients with positive reactions to sodium tetrachloropalladate, Myroxylon pereirae, caine mix II, and palladium chloride., Results: A total of 5446 patients had been tested with FC during the study period. There was a significant overrepresentation of contact allergy to Al among patients with positive reactions to sodium tetrachloropalladate, Myroxylon pereirae, caine mix II, and palladium chloride. Patients with a strong Al allergy had significantly higher amounts of concomitant reactions to sodium tetrachloropalladate, Myroxylon pereirae, caine mix II, and palladium chloride compared to patients with weak Al allergy. These results were not seen for patients tested with Finn Chambers AQUA., Conclusion: In patients with contact allergy to Al, patch testing with Finn chambers could give false-positive reactions to sodium tetrachloropalladate, Myroxylon pereirae, caine mix II, and palladium chloride., (© 2021 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
47. COVID-19 vaccine perceptions among South Asian communities in the UK: An application of the theory of planned behavior.
- Author
-
Akbar, M. Bilal, Singh, Lakhbir, Deshpande, Sameer, and Amoncar, Nihar
- Subjects
QUALITATIVE research ,CONTROL (Psychology) ,DRUG side effects ,VACCINATION ,PLANNED behavior theory ,INTERVIEWING ,VACCINE refusal ,COMMUNITIES ,COVID-19 vaccines ,FAMILIES ,SOUTH Asians ,ATTITUDE (Psychology) ,THEMATIC analysis ,RESEARCH methodology ,DRUG efficacy ,HEALTH education ,HEALTH promotion ,COVID-19 - Abstract
Based on the Theory of Planned Behavior, this paper explores the perceptions of the COVID-19 vaccine among South Asian communities residing in the UK. Thirty-eight semi-structured interviews were conducted using a qualitative approach and analyzed using thematic analysis. Participants represented Indian, Pakistani, Bangladeshi, Sri Lankan, Afghani, and Nepali backgrounds. The participants revealed that family and community influence their perceptions of the COVID-19 vaccine. The results suggest that normalizing vaccine acceptance, addressing unknown side effects, and popularizing vaccine efficacy data will increase vaccine uptake within the South Asian community in the UK. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
48. The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer.
- Author
-
Conarty, Jacob P. and Wieland, Andreas
- Subjects
HEAD & neck cancer ,PAPILLOMAVIRUSES ,OROPHARYNX ,HUMAN papillomavirus ,SQUAMOUS cell carcinoma ,IMMUNE response ,WESTERN countries - Abstract
Human papillomaviruses (HPVs) are the causative agent of several anogenital cancers as well as head and neck cancers, with HPV+ head and neck squamous cell carcinoma (HNSCC) becoming a rapidly growing public health issue in the Western world. Due its viral etiology and potentially its subanatomical location, HPV+ HNSCC exhibits an immune microenvironment which is more inflamed and thus distinct from HPV-negative HNSCC. Notably, the antigenic landscape in most HPV+ HNSCC tumors extends beyond the classical HPV oncoproteins E6/7 and is extensively targeted by both the humoral and cellular arms of the adaptive immune system. Here, we provide a comprehensive overview of HPV-specific immune responses in patients with HPV+ HNSCC. We highlight the localization, antigen specificity, and differentiation states of humoral and cellular immune responses, and discuss their similarities and differences. Finally, we review currently pursued immunotherapeutic treatment modalities that attempt to harness HPV-specific immune responses for improving clinical outcomes in patients with HPV+ HNSCC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
49. NEW CONTACT ALLERGENS AND EXPOSURES IN THE HOME AND ENVIRONMENT: AN UPDATE.
- Author
-
Aerts, Olivier, Dendooven, Ella, and Goossens, An
- Subjects
ALLERGENS ,CONSUMER goods ,SKIN inflammation ,SKIN disease treatment ,DISEASE management ,MEDICAL personnel - Abstract
New chemicals are continually being introduced in consumer products such as cosmetics, pharmaceuticals, medical devices, textiles, tattoo inks, rubber materials and footwear. Allergic contact dermatitis (ACD) arising from new sensitisers in such items is a frequent problem in daily practice, and a correct diagnosis is often difficult. In this overview we provide a practical update illustrated by clinical examples of new and sometimes unexpected sensitisers and some old ones in new applications. Notable examples include the emergence of amino acid alkyl amides (AAAs), vitamin C compounds, resorcinol derivatives, glycols, metals (eg tin) and lipid/carbohydrate allergens in cosmetics; benzophenone residues in octocrylene-containing sunscreens, plastics and inks; the replacement of tosylamide/formaldehyde resin in nail varnishes by sensitising copolymers based on phthalic anhydride/adipic acid and (meth)acrylates; epoxy resin as a non-occupational contact allergen in domestically used glues; fragrances (including terpenes) in, for example, (medical) adhesives; persulfates in hot-tub detergents; isothiazolinones in leather wear and rubber gloves; chemicals such as chlorophenols in textiles and acetophenone azine in foot and sportswear; biguanides and quaternary ammonium salts used as antimicrobial agents in cosmetic and non-cosmetic products (eg wound-care products); acrylates and silicone components in medical devices. [ABSTRACT FROM AUTHOR]
- Published
- 2023
50. Effects of aluminium chloride added to common patch test substances.
- Author
-
Comstedt, Lisbeth Rosholm, Siemund, Ingrid, Dahlin, Jakob, Bruze, Magnus, and Svedman, Cecilia
- Subjects
ALUMINUM chloride ,NICKEL sulfate ,WILCOXON signed-rank test ,ALLERGENS - Abstract
Background: A modulating effect of aluminium regarding type IV reactions might exist but has not been further investigated. Objectives: The aim of this study was to investigate the effect on patch test reactions when adding aluminium chloride hexahydrate (Al‐Cl) to common test preparations. Materials and methods: Al‐Cl in different concentrations was added to nickel sulphate 15.0% aqua (Ni), methylisothiazolinone 0.2% aqua (MI) and fragrance mix I 10.0% aqua/ethanol (FM I). The Ni preparations were tested in 120 consecutive patients. MI and FM I were tested in participants known to have contact allergy to the respective allergen. McNemar's test was used to decide which Ni preparation had the highest sensitivity. Wilcoxon signed‐rank test was used to calculate pairwise comparison in summarized test score for the preparations with MI and FM I. Results: Adding Al‐Cl 20.0%/30.0% to Ni identified twice as many patients with contact allergy to nickel compared to Ni without Al‐Cl. Adding Al‐Cl 20.0%/10.0% to MI, decreased the patch test reactivity compared to MI without Al‐Cl. No differences in patch reactivity were noticed when adding Al‐Cl to FM I. Conclusion: Al‐Cl 20.0% or 30.0% seems to enhance the patch test reactivity to Ni 15.0% aqua. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.